- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06657547
Urinary Concentration After Salmeterol
April 7, 2025 updated by: Morten Hostrup, PhD, University of Copenhagen
Urinary Concentration After Salmeterol in Well-trained Men and Females
The purpose of the project is to investigate urine concentration after inhalation of salmeterol.
This will be examined following acute physical activity under both normal conditions and heated conditions.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Morten Hostrup, PhD
- Phone Number: +4535321595
- Email: mhostrup@nexs.ku.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Recruiting
- August Krogh Building
-
Contact:
- Morten Hostrup, PhD
- Phone Number: +4535321595
- Email: mhostrup@nexs.ku.dk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Inclusion Criteria:
- Age 18-40
- Physically active >5 hours a week
- Maximum oxygen uptake classified as high or very high
Exclusion Criteria:
- Active smoker currently or within the past 5 years
- Regular intake of medication deemed by the responsible study physician to affect the test parameters (hormonal contraception is accepted for women)
- Chronic or acute illness deemed by the responsible study physician to affect the test parameters
- Deviation from the study protocol
- Lean mass index >21 kg/m²
- Pregnancy
- Smoker
- Blood donation during the past 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Normal conditions
Urine samples collected after various performance tests in normal conditions
|
Participants are administered salmeterol, after which they perform various performance tests in normal conditions.
Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
|
|
Experimental: Heated conditions
Urine samples collected after various performance tests in heated conditions
|
Participants are administered salmeterol, after which they perform various performance tests in heated conditions.
Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
|
|
Other: Salmeterol inhalation and urine samples
Participants are administered daily salmeterol inhalation from an MDI device and are required to collect spot urine samples at home.
|
After the experimental day under normal conditions, all participants are administered 200 µg of salmeterol daily (8 puffs from the MDI device) during a 6-day intervention period.
Two hours after inhalation, the participants collect spot urine samples at home
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Urine concentration
Time Frame: Through study completion, an average on 1 week
|
Difference in urine concentration with salmeterol administered before performance tests in different conditions
|
Through study completion, an average on 1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 31, 2024
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
October 23, 2024
First Submitted That Met QC Criteria
October 23, 2024
First Posted (Actual)
October 24, 2024
Study Record Updates
Last Update Posted (Actual)
April 9, 2025
Last Update Submitted That Met QC Criteria
April 7, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Agents
- Adrenergic Agonists
- Adrenergic Agents
- Respiratory System Agents
- Anti-Asthmatic Agents
- Bronchodilator Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Salmeterol Xinafoate
Other Study ID Numbers
- SALM_urine
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.